Review



anti psat1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech anti psat1
    Anti Psat1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/10501+1+ap/pm41925099-62-9-16?v=Proteintech
    Average 96 stars, based on 108 article reviews
    anti psat1 - by Bioz Stars, 2026-08
    96/100 stars

    Images



    Similar Products

    anti psat1  (Proteintech)
    96
    Proteintech anti psat1
    Anti Psat1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/10501+1+ap/pm41925099-62-9-16?v=Proteintech
    Average 96 stars, based on 1 article reviews
    anti psat1 - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    psat1  (Proteintech)
    96
    Proteintech psat1
    Psat1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/10501+1+ap/pm41760625-326-21-23?v=Proteintech
    Average 96 stars, based on 1 article reviews
    psat1 - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    psat1 primary antibody  (Proteintech)
    96
    Proteintech psat1 primary antibody
    Detection of <t>PSAT1</t> expression and its correlation analysis with clinical characteristics. (A) Pan‐cancer analysis of the expression of PSAT1 in the TIMER database. (B) The expression of PSAT1 mRNA in LUAD tissues in the TCGA database. (C) The expression of PSAT1 mRNA in paired tumor tissues and adjacent normal tissues in the TCGA database. (D–G) The clinical correlations between the expression of PSAT1 and age, gender, stage, and lymph node metastasis. (H) The immunohistochemical results of PSAT1 in the tumor tissues of tumor‐bearing mice. (I) The results of quantitative analysis of immunohistochemistry ( n = 3). (J) Representative PSAT1 immunofluorescence results in A549 cells. (K) PSAT1 relative fluorescence intensity ( n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001.
    Psat1 Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/10501+1+ap/pmc12907970-89-4-7?v=Proteintech
    Average 96 stars, based on 1 article reviews
    psat1 primary antibody - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Detection of PSAT1 expression and its correlation analysis with clinical characteristics. (A) Pan‐cancer analysis of the expression of PSAT1 in the TIMER database. (B) The expression of PSAT1 mRNA in LUAD tissues in the TCGA database. (C) The expression of PSAT1 mRNA in paired tumor tissues and adjacent normal tissues in the TCGA database. (D–G) The clinical correlations between the expression of PSAT1 and age, gender, stage, and lymph node metastasis. (H) The immunohistochemical results of PSAT1 in the tumor tissues of tumor‐bearing mice. (I) The results of quantitative analysis of immunohistochemistry ( n = 3). (J) Representative PSAT1 immunofluorescence results in A549 cells. (K) PSAT1 relative fluorescence intensity ( n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Animal Models and Experimental Medicine

    Article Title: Bioinformatics‐based discovery of the involvement of PSAT1 in mediating the anti‐lung adenocarcinoma activity of triptolide

    doi: 10.1002/ame2.70120

    Figure Lengend Snippet: Detection of PSAT1 expression and its correlation analysis with clinical characteristics. (A) Pan‐cancer analysis of the expression of PSAT1 in the TIMER database. (B) The expression of PSAT1 mRNA in LUAD tissues in the TCGA database. (C) The expression of PSAT1 mRNA in paired tumor tissues and adjacent normal tissues in the TCGA database. (D–G) The clinical correlations between the expression of PSAT1 and age, gender, stage, and lymph node metastasis. (H) The immunohistochemical results of PSAT1 in the tumor tissues of tumor‐bearing mice. (I) The results of quantitative analysis of immunohistochemistry ( n = 3). (J) Representative PSAT1 immunofluorescence results in A549 cells. (K) PSAT1 relative fluorescence intensity ( n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Sections were incubated with PSAT1 primary antibody (Proteintech) overnight at 4°C, washed, and then incubated with secondary antibody.

    Techniques: Expressing, Immunohistochemical staining, Immunohistochemistry, Immunofluorescence, Fluorescence

    Evaluation of the anti‐tumor efficacy of TP in PSAT1‐overexpressing cells. (A) RT‐qPCR detection of PSAT1 mRNA expression in the A549 overexpression model. (B) Cell viability of A549 cells after 24 h of TP treatment at different concentrations. (C) Cell viability of A549 cells after 48 h of TP treatment at different concentrations. (D) Representative results of the wound healing assay (TP: 60 nmol/L, n = 3, scale bar: 200 μm). (E) Cell migration rate at 24 h ( n = 3). (F) Cell migration rate at 48 h ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Animal Models and Experimental Medicine

    Article Title: Bioinformatics‐based discovery of the involvement of PSAT1 in mediating the anti‐lung adenocarcinoma activity of triptolide

    doi: 10.1002/ame2.70120

    Figure Lengend Snippet: Evaluation of the anti‐tumor efficacy of TP in PSAT1‐overexpressing cells. (A) RT‐qPCR detection of PSAT1 mRNA expression in the A549 overexpression model. (B) Cell viability of A549 cells after 24 h of TP treatment at different concentrations. (C) Cell viability of A549 cells after 48 h of TP treatment at different concentrations. (D) Representative results of the wound healing assay (TP: 60 nmol/L, n = 3, scale bar: 200 μm). (E) Cell migration rate at 24 h ( n = 3). (F) Cell migration rate at 48 h ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Sections were incubated with PSAT1 primary antibody (Proteintech) overnight at 4°C, washed, and then incubated with secondary antibody.

    Techniques: Quantitative RT-PCR, Expressing, Over Expression, Wound Healing Assay, Migration